EA201990189A1 - Синтез n-(гетероарил)пирроло[3,2-d]пиримидин-2-аминов - Google Patents

Синтез n-(гетероарил)пирроло[3,2-d]пиримидин-2-аминов

Info

Publication number
EA201990189A1
EA201990189A1 EA201990189A EA201990189A EA201990189A1 EA 201990189 A1 EA201990189 A1 EA 201990189A1 EA 201990189 A EA201990189 A EA 201990189A EA 201990189 A EA201990189 A EA 201990189A EA 201990189 A1 EA201990189 A1 EA 201990189A1
Authority
EA
Eurasian Patent Office
Prior art keywords
synthesis
pyrrolo
pyrimidin
heteroaryl
amines
Prior art date
Application number
EA201990189A
Other languages
English (en)
Inventor
Александр Смит
Ханна С. Уайт
Франсис Ксавьер Таварес
Сергий Красутский
Цзянь-Се Чэнь
Роберта Л. Дорроу
Хуа Чжон
Original Assignee
Г1 Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Г1 Терапьютикс, Инк. filed Critical Г1 Терапьютикс, Инк.
Publication of EA201990189A1 publication Critical patent/EA201990189A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Изобретение относится к области синтеза соединений на основе пиримидина, применимых для лечения нарушений, характеризующихся аномальной клеточной пролиферацией, включая, но без ограничения, опухоли и различные виды рака.
EA201990189A 2016-07-01 2017-06-29 Синтез n-(гетероарил)пирроло[3,2-d]пиримидин-2-аминов EA201990189A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662357797P 2016-07-01 2016-07-01
PCT/US2017/040102 WO2018005865A1 (en) 2016-07-01 2017-06-29 Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines

Publications (1)

Publication Number Publication Date
EA201990189A1 true EA201990189A1 (ru) 2019-06-28

Family

ID=60786476

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990189A EA201990189A1 (ru) 2016-07-01 2017-06-29 Синтез n-(гетероарил)пирроло[3,2-d]пиримидин-2-аминов

Country Status (13)

Country Link
US (2) US10865210B2 (ru)
EP (1) EP3478295A4 (ru)
JP (1) JP7106462B2 (ru)
KR (1) KR102445288B1 (ru)
CN (1) CN109789142B (ru)
AU (2) AU2017290362B2 (ru)
BR (1) BR112018077155A2 (ru)
CA (1) CA3028752A1 (ru)
EA (1) EA201990189A1 (ru)
IL (1) IL263911B (ru)
MX (1) MX2019000199A (ru)
NZ (1) NZ749275A (ru)
WO (1) WO2018005865A1 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6337083B2 (ja) 2013-03-15 2018-06-06 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
WO2018129387A1 (en) 2017-01-06 2018-07-12 G1 Therapeutics, Inc. Combination therapy for the treatment of cancer
CA3070073A1 (en) 2017-07-18 2019-01-24 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
SG11202000418XA (en) 2017-07-18 2020-02-27 Nuvation Bio Inc Heterocyclic compounds as adenosine antagonists
KR20200131246A (ko) 2018-02-15 2020-11-23 누베이션 바이오 인크. 키나제 억제제로서의 헤테로시클릭 화합물
CN108299317A (zh) * 2018-03-20 2018-07-20 爱斯特（成都）生物制药股份有限公司 1,4-二氮杂螺[5,5]十一烷盐酸盐的合成方法
CN114366743A (zh) * 2018-04-09 2022-04-19 G1治疗公司 具有驱动致癌突变的癌症的治疗
CN108840814B (zh) * 2018-07-24 2021-09-24 南京药石科技股份有限公司 一种8-氧代-2,6,9-三氮杂螺[4.5]癸烷-2-羧酸叔丁酯制备方法
WO2020041770A1 (en) * 2018-08-24 2020-02-27 G1 Therapeutics, Inc. Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one
US11254670B2 (en) 2019-01-18 2022-02-22 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
MX2021008650A (es) 2019-01-18 2021-11-03 Nuvation Bio Inc Compuestos heterociclicos como antagonistas de adenosina.
AU2021273744A1 (en) 2020-05-19 2022-12-08 G1 Therapeutics, Inc. Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
EP4164653A1 (en) * 2020-06-15 2023-04-19 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
WO2022076779A1 (en) 2020-10-08 2022-04-14 Teva Pharmaceuticals International Gmbh Solid state forms of trilaciclib and of trilaciclib salts
CN113788837B (zh) * 2021-08-02 2022-08-26 深圳湾实验室坪山生物医药研发转化中心 Trilaciclib的合成方法
CN113754600A (zh) * 2021-11-10 2021-12-07 天津敬康生物科技有限公司 1,4-二氮杂螺[5,5]十一烷-3-酮的制备方法
CN114014863B (zh) * 2021-12-21 2022-11-29 武汉九州钰民医药科技有限公司 骨髓保护剂曲拉西利的制备方法
CN114014864B (zh) * 2021-12-21 2022-11-25 武汉九州钰民医药科技有限公司 一种曲拉西利化合物的制备工艺
WO2023164255A1 (en) * 2022-02-28 2023-08-31 Teva Pharmaceuticals International Gmbh Crystalline forms of trilaciclib and trilaciclib salts
US11958751B2 (en) * 2022-06-27 2024-04-16 Saudi Arabian Oil Company Method of synthesizing materials integrating supernatant recycle
CN115477653B (zh) * 2022-10-11 2024-04-09 安徽省庆云医药股份有限公司 一种曲拉西利关键中间体及曲拉西利的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506760B1 (en) * 2000-04-14 2003-01-14 Corvas International, Inc. Substituted hydrazinyl heteroaromatic inhibitors of thrombin
ATE408613T1 (de) * 2000-08-04 2008-10-15 Warner Lambert Co 2-(4-pyridyl)amino-6-dialkoxyphenyl-pyrido(2,3- d)pyrimidin-7-one
US7399763B2 (en) * 2002-09-11 2008-07-15 Merck & Co., Inc. 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as HIV integrase inhibitors
WO2004065378A1 (en) * 2003-01-17 2004-08-05 Warner-Lambert Company Llc 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
ATE378339T1 (de) 2004-01-08 2007-11-15 Hoffmann La Roche Diazaspiropiperidinderivate als inhibitoren von glycintransporter 1 und glycintransporter 2
JP2008512460A (ja) 2004-09-08 2008-04-24 メルク エンド カムパニー インコーポレーテッド 単環式アニリドスピロラクタムｃｇｒｐ受容体拮抗薬
JP2008512456A (ja) 2004-09-09 2008-04-24 メルク エンド カムパニー インコーポレーテッド 三環式アニリドスピロラクタムｃｇｒｐ受容体拮抗薬
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
ATE464305T1 (de) 2004-09-13 2010-04-15 Merck Sharp & Dohme Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
US7851464B2 (en) 2005-11-18 2010-12-14 Merck Sharp & Dohme Corp. Spirolactam aryl CGRP receptor antagonists
EP2091533B1 (en) 2006-12-08 2012-11-28 Merck Sharp & Dohme Corp. Constrained spirocyclic compounds as cgrp receptor antagonists
WO2008109464A1 (en) 2007-03-02 2008-09-12 University Of Massachusetts Spirolactam targeting compounds and related compounds
KR20110002475A (ko) * 2008-04-22 2011-01-07 아스트라제네카 아베 치환 피리미딘-5-카르복시아미드 281
WO2010020675A1 (en) 2008-08-22 2010-02-25 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
CN103429243B (zh) 2010-10-25 2016-06-08 G1治疗公司 Cdk抑制剂
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
US8829102B2 (en) 2010-10-27 2014-09-09 Cabot Corporation High loading carbon black masterbatch for pressure pipe applications
WO2013148748A1 (en) 2012-03-29 2013-10-03 Francis Xavier Tavares Lactam kinase inhibitors
CN104302620A (zh) 2012-04-26 2015-01-21 弗朗西斯·泽维尔·塔瓦雷斯 内酰胺的合成
WO2013169574A2 (en) 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Aliphatic spirolactam cgrp receptor antagonists
US20140274896A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
JP6435315B2 (ja) * 2013-03-15 2018-12-05 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 高活性抗新生物薬及び抗増殖剤
JP6337083B2 (ja) 2013-03-15 2018-06-06 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療
MX369503B (es) 2013-04-08 2019-11-11 Pharmacyclics Llc Combinaciones que comprenden ibrutinib y abt-199 para tratar trastornos proliferativos de células b y métodos de uso de las mismas.
US20150031674A1 (en) * 2013-07-26 2015-01-29 Genentech, Inc. Serine/threonine kinase inhibitors
US20160257688A1 (en) 2013-10-24 2016-09-08 Francis Xavier Tavares Process for Synthesis of Lactams
US9481591B1 (en) 2013-12-16 2016-11-01 Barbara Blake Device and process to treat and disinfect sewage, food processing wastewater and other biologically contaminated water
WO2015161283A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
CN105622638B (zh) * 2014-10-29 2018-10-02 广州必贝特医药技术有限公司 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
RU2726631C1 (ru) 2017-01-23 2020-07-15 Пфайзер Инк. Гетероциклические спиросоединения в качестве ингибиторов magl

Also Published As

Publication number Publication date
KR102445288B1 (ko) 2022-09-19
US20210122755A1 (en) 2021-04-29
JP7106462B2 (ja) 2022-07-26
US20190135820A1 (en) 2019-05-09
WO2018005865A1 (en) 2018-01-04
RU2019102643A3 (ru) 2020-08-21
IL263911A (en) 2019-01-31
AU2021261879A1 (en) 2021-12-02
AU2021261879B2 (en) 2024-01-04
IL263911B (en) 2021-10-31
NZ749275A (en) 2023-06-30
RU2019102643A (ru) 2020-08-03
KR20190025651A (ko) 2019-03-11
US10865210B2 (en) 2020-12-15
CN109789142A (zh) 2019-05-21
AU2017290362B2 (en) 2021-08-05
BR112018077155A2 (pt) 2019-04-02
CA3028752A1 (en) 2018-01-04
EP3478295A1 (en) 2019-05-08
AU2017290362A1 (en) 2019-01-17
JP2019520380A (ja) 2019-07-18
MX2019000199A (es) 2019-09-23
US11629150B2 (en) 2023-04-18
CN109789142B (zh) 2022-08-23
EP3478295A4 (en) 2019-12-04

Similar Documents

Publication Publication Date Title
EA201990189A1 (ru) Синтез n-(гетероарил)пирроло[3,2-d]пиримидин-2-аминов
EA201990187A1 (ru) Антипролиферационные средства на основе пиримидина
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
EA201792529A1 (ru) Ингибиторы тирозинкиназы
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
EA201890125A1 (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
EA201791507A1 (ru) Пирроло- и пиразолопиримидины в качестве ингибиторов убиквитин- специфичной протеазы 7
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
PH12016501107A1 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
EA201690316A1 (ru) Соединения для применения в качестве иммуномодуляторов
EA201591823A1 (ru) Ингибиторы ido
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201790085A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
EA201990400A1 (ru) Соединения и композиции и их применение
EA201790327A1 (ru) Соединения замещенного пиперидина
EA202090414A1 (ru) Соединения и их применение
SG10201900954SA (en) Heterocycles as Modulators of Kinase Activity
EA201992302A1 (ru) Соединения, используемые в качестве ингибиторов alcat1